Skip to main content

Table 6 Test properties of anti-RNAP for the prediction of various clinical manifestations in systemic sclerosis

From: Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort

Clinical manifestation a Sensitivity (95% CI) Specificity (95% CI) Positive predictive value (95% CI) Negative predictive value (95% CI)
Diffuse subtype 14.7% (11.2 to 18.8%) 82.5% (73.4 to 89.5%) 75.4% (63.5 to 84.9%) 20.9% (17.0 to 25.4%)
Joint contracture 30.7% (23.8 to 38.3%) 93.7% (90.2 to 96.2%) 73.9% (61.9 to 83.8%) 69.9% (65.0 to 74.5%)
Synovitis 22.5% (14.6 to 32.0%) 86.7% (82.7 to 90.1% 31.9% (21.2 to 44.2%) 80.1% (75.7 to 84.0%)
Myositisb 50.0% (6.8 to 93.2%) 85.0% (81.4 to 88.2%) 2.9% (0.4 to 10.1%) 99.5% (98.1 to 99.9%)
Systemic hypertension 21.6% (16.0 to 28.1%) 89% (84.5 92.6%) 59.4% (46.9 to 71.1%) 60.3% (55.1 to 65.3%)
Renal crisis 70.8% (48.9 to 87.4%) 87.8% (84.3 to 90.8%) 24.6% (15.1 to 36.5%) 98.2% (96.3 to 99.3%)
Malignancyb (all types) 21.9% (12.5 to 34.0%) 85.8% (81.9 to 89.1%) 20.3% (11.6 to 31.7%) 86.9% (83.1 to 90.1%)
Malignancyb,c (certain types) 20.8% (10.5 to 35.0%) 85.8% (81.9 to 89.1%) 15.4% (7.6 to 2.6%) 89.7% (86.2 to 92.6%)
Malignancy within 5 years of SSc onsetc 37.5% (15.2 to 64.6%) 86.2% (81.7 to 90.0%) 13.3% (5.1 to 16.8%) 96.1% (92.9 to 98.1%)
  1. anti-RNAP, anti-RNA polymerase III antibodies; CI, confidence interval; SSc, systemic sclerosis. aEver from disease onset to most recent visit; except for malignancy, which was ever from birth to most recent visit. bChi-square P > 0.05 in univariate analysis. cExcluding nonmelanoma skin cancers and the 'other' category.